Filter
482
Text search:
Pharmaceutical
Prices
Featured
Recommendations
39
New Publications
135
Language
Document type
No document type
238
Studies & Reports
132
Guidelines
51
Strategic & Response Plan
25
Manuals
17
Fact sheets
8
Situation Updates
6
Training Material
4
Resource Platforms
1
Countries / Regions
India
21
Global
21
Kenya
16
Uganda
14
Sierra Leone
9
Ghana
9
Ukraine
9
Liberia
8
Nigeria
8
Zambia
8
Tanzania
8
Ethiopia
7
Philippines
7
Syria
7
South Africa
7
Malawi
7
Zimbabwe
6
Nepal
6
Indonesia
6
Congo, Democratic Republic of
5
Bangladesh
5
Namibia
5
Western and Central Europe
5
Senegal
4
Cameroon
4
Rwanda
4
Botswana
4
Myanmar / Burma
4
Latin America and the Carribbean
4
Venezuela
4
Haiti
3
Mozambique
3
Lesotho
3
Africa
3
Eastern Europe
3
Pakistan
2
Germany
2
Papua New Guinea
2
Benin
2
Eswatini/ Swaziland
2
Albania
2
Burkina Faso
1
Mali
1
Niger
1
South Sudan
1
Jordan
1
Afghanistan
1
Lebanon
1
Egypt
1
Chad
1
Cambodia
1
China
1
Sudan
1
Central African Republic
1
North Macedonia
1
Libya
1
Sri Lanka
1
West and Central Africa
1
Middle East and North Africa
1
South–East Asia Region
1
Eastern Europe and Central Asia
1
Paraguay
1
Mongolia
1
Southern Africa
1
Laos
1
Bulgaria
1
Lithuania
1
Kyrgyzstan
1
Gabon
1
Turkmenistan
1
Authors & Publishers
Publication Years
Category
Countries
201
Clinical Guidelines
35
Public Health
17
Pharmacy & Technologies
13
Key Resources
12
Women & Child Health
9
Capacity Building
2
Toolboxes
Pharmacy
57
AMR
44
HIV
40
COVID-19
40
Mental Health
30
TB
14
Global Health Education
12
Health Financing Toolbox
12
Conflict
10
Planetary Health
8
NTDs
8
NCDs
7
Caregiver
5
Ebola & Marburg
4
Disability
3
Refugee
3
Polio
2
Malaria
2
Cholera
1
Natural Hazards
1
Rapid Response
1
2.0 Rapid Response
1
Compilation of country case studies and best practices. World Health Report (2010) Background Paper, 25
Antimicrobial resistance (AMR) is occurring everywhere in the world, compromising the ability to treat infectious diseases, as well as undermining many other advances in health and medicine. Underlying factors that drive AMR include; weak or absent surveillance and monitoring systems, inadequate sys
...
Agodokpessi et al. Journal of Pharmaceutical Policy and Practice (2015) 8:12DOI 10.1186/s40545-015-0033-7
Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated
the operation of the RDF and assessed wh
...
The purpose of this manual is to define a limited number of indicators that will objectively describe the management and use of antimicrobials in hospitals and to provide tools and step-by-step instructions for designing and carrying out an assessment of antibiotic use and management in hospitals. T
...
English version - This handbook sets out a the new paradigm for pharmacy practice. Its aim is to guide pharmacy educators in pharmacy practice, to educate pharmacy students and to guide pharmacists in practice to update their skills. The handbook, which brings together practical tools and knowledge,
...
High prices, hard-to-access human insulin, few insulin producers, and weak health systems are just some of the barriers that people with diabetes face a century after insulin was discovered, WHO notes in a new report
This interagency report provides recommendations for assuring quality of medicines during key activities of country-level procurement agencies, namely prequalification of pharmaceutical products and manufacturers; purchase of
...
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically
...
The pharmaceutical sector of any nation is responsible for providing society with quality medicines and other pharmaceutical services. According to the World Health Organization (WHO), Pharmaceutica
...
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and safety and comparative cost-effectiveness. They are intended to be available in functioning health
...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
